Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.62 |
| ▸ | PTPRC | P08575 | 1/20 | 0.60 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | KLK7 | P49862 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | SGMS1 | Q86VZ5 | 1/20 | 0.51 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.50 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2349758 | 0.92 | NAMPT (0.70) | NAMPTPTPRCPTPN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL839348 | 0.89 | NAMPT (0.66) | NAMPTPTPRCPTPN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL23099714 | 0.88 | KMT2A (0.60) | NAMPTPTPRCPTPN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL1931512 | 0.88 | NAMPT (0.65) | NAMPTPTPRCPTPN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL25547335 | 0.85 | NAMPT (0.62) | NAMPTPTPRCPTPN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL2003113 | 0.85 | NAMPT (0.62) | NAMPTPTPRCPTPN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL19932361 | 0.85 | NAMPT (0.62) | NAMPTPTPRCPTPN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL7646959 | 0.84 | MEN1 (0.54) | NAMPTPTPRCPTPN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL418094 | 0.84 | MEN1 (0.60) | NAMPTPTPRCPTPN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL8864260 | 0.82 | SMN1; SMN2 (0.69) | NAMPTPTPRCPTPN1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411362-B1 | Tricyclic indole derivatives as PBR ligands | GE HEALTHCARE LTD (GB) | 2017-05-31 | — | — | EP | disclosed |
| CN-103179991-B | In vivo imaging method for cancer | 通用电气健康护理有限公司 | 2016-08-24 | — | — | CN | disclosed |
| US-9314541-B2 | In vivo imaging method for cancer | GE HEALTHCARE LIMITED (GB) | 2016-04-19 | — | — | US | disclosed |
| US-9220795-B2 | Indole derivatives | GE HEALTHCARE LIMITED (GB) | 2015-12-29 | — | — | US | disclosed |
| US-9168317-B2 | In vivo imaging method of mood disorders | GE HEALTHCARE LIMITED (GB) | 2015-10-27 | — | — | US | disclosed |
| US-20140364615-A1 | INDOLE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2014-12-11 | — | — | US | disclosed |
| US-8790619-B2 | Indole derivatives | GE HEALTHCARE LIMITED (GB) | 2014-07-29 | — | — | US | disclosed |
| EP-2621544-A1 | IN VIVO IMAGING METHOD FOR CANCER | GE Healthcare UK Limited (GB) | 2013-08-07 | — | — | EP | disclosed |
| EP-2618850-A1 | IN VIVO IMAGING METHOD OF MOOD DISORDERS | GE Healthcare UK Limited (GB) | 2013-07-31 | — | — | EP | disclosed |
| US-20130183240-A1 | IN VIVO IMAGING METHOD FOR CANCER | GE HEALTHCARE LIMITED (GB) | 2013-07-18 | — | — | US | disclosed |
| CN-103209713-A | In vivo imaging method of mood disorders | GE HEALTHCARE LTD | 2013-07-17 | — | — | CN | disclosed |
| US-20130177501-A1 | IN VIVO IMAGING METHOD OF MOOD DISORDERS | GE HEALTHCARE LIMITED (GB) | 2013-07-11 | — | — | US | disclosed |
| CN-103179991-A | In vivo imaging method for cancer | GE HEALTHCARE LTD | 2013-06-26 | — | — | CN | disclosed |
| WO-2012041953-A1 | IN VIVO IMAGING METHOD FOR CANCER | GE HEALTHCARE LIMITED (GB) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012038532-A1 | IN VIVO IMAGING METHOD OF MOOD DISORDERS | GE HEALTHCARE LIMITED (GB) | 2012-03-29 | — | — | WO | disclosed |
| EP-2411362-A2 | INDOLE DERIVATIVES | GE Healthcare UK Limited (GB) | 2012-02-01 | — | — | EP | disclosed |
| US-20120020884-A1 | INDOLE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2012-01-26 | — | — | US | disclosed |
| WO-2010109007-A2 | INDOLE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2010-09-30 | — | — | WO | disclosed |
| US-5616799-A | REACTING A CORRESPONDING NITRO COMPOUND WITH A KETONE AND HYDROGEN IN PRESENCE OF A NOBLE METAL CATALYST | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120020884-A1 | INDOLE DERIVATIVES | IDO1, IDO2, INMT | NAMPT 2744/4885PTPRC 4293/4885PTPN1 4766/4885 |
| US-20130183240-A1 | IN VIVO IMAGING METHOD FOR CANCER | MKI67, PBRM1, BRD4 | NAMPT 1544/4885PTPRC 3153/4885PTPN1 4744/4885 |
| US-20140364615-A1 | INDOLE DERIVATIVES | IDO1, IDO2, INMT | NAMPT 2744/4885PTPRC 4293/4885PTPN1 4766/4885 |
| US-20130177501-A1 | IN VIVO IMAGING METHOD OF MOOD DISORDERS | SLC18A2, SLC6A2, SLC6A4 | NAMPT 1331/4885PTPRC 2916/4885PTPN1 4104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.